Skip to main content
Premium Trial:

Request an Annual Quote

Roche's Cobas CMV Viral Load Assay Gets CE Mark

NEW YORK (GenomeWeb) – Roche today announced that its Cobas CMV viral load assay for human cytomegalovirus has received CE marking.

The real-time PCR-based assay, which runs on the Cobas 6800/8800 systems, meets the first World Health Organization International Standard for Human Cytomegalovirus for Nucleic Acid Amplification Techniques and, therefore, provides consistent and reliable results for monitoring the viral load in transplant patients receiving an anti-viral therapy, Roche said in a statement.

"The unparalleled performance and unmatched flexibility of the Cobas 6800/8800 systems allows laboratories to ensure rapid turn-around time for critical tests, like Cobas CMV, while still delivering routine viral load monitoring results," Paul Brown, head of Roche Molecular Diagnostics, said. "Cobas CMV is harmonized to the WHO standard to ensure that laboratories and clinicians can rely on this test, leading to increased quality of care and comparable results across different labs for patients infected with CMV."

Roche said that the HCV assay is the penultimate step in completing the viral load monitoring portfolio for the Cobas 6800/8800 systems and will be followed by the release of the Cobas HBV assay for hepatitis B in the first quarter of 2015.

The Cobas CMV assay and the 6800/8800 systems are commercially available in markets that recognize the CE mark and are not currently available in the US.

Roche recently announced that its Cobas HIV-1 and HCV assays running on the Cobas 6800/8800 systems also received CE marking. Roche currently offers a qPCR-based CMV assay, available for the Cobas p 630 instrument.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.